Physician profile
Gregory Ackert
NPI 1417991803
$2,054.03
in general payments reported to CMS, 2019-2025
21 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $51.44 · 2021: $195 · 2022: $537 · 2023: $281 · 2024: $720 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $308.28 | 2019-2025 | Watchman Flx, Watchman Access System |
| Celgene Corporation | $204.87 | 2022-2024 | Zeposia |
| Abbvie INC. | $196.38 | 2021-2024 | Ubrelvy |
| Cvrx, INC. | $190.50 | 2022 | |
| Janssen Biotech, INC. | $176.68 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.33 | 2021-2024 | Xifaxan |
| Lilly USA, LLC | $144.49 | 2022-2024 | Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $124.56 | 2024 | Voquezna |
| Novo Nordisk INC | $114.85 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $87.85 | 2019-2025 | Merlin@Home |
| Pfizer INC. | $61.74 | 2020-2024 | |
| Glaxosmithkline, LLC. | $57.11 | 2021-2024 | Trelegy Ellipta |
| Genzyme Corporation | $35.21 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.69 | 2019-2024 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $29.68 | 2024 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $27.09 | 2023 | Arikayce |
| Inspire Medical Systems, INC. | $26.35 | 2025 | Inspire |
| Itamar Medical INC | $25.39 | 2022 | |
| Philips North America LLC | $20.70 | 2024 | (5044) Mcot |
| Merck Sharp & Dohme LLC | $20.34 | 2024 | Verquvo |
| Amgen INC. | $19.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ackert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.